USS Investment Management Ltd Acquires 5,040 Shares of Becton, Dickinson and Company $BDX

USS Investment Management Ltd boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 9.4% in the first quarter, HoldingsChannel.com reports. The firm owned 58,516 shares of the medical instruments supplier’s stock after buying an additional 5,040 shares during the period. USS Investment Management Ltd’s holdings in Becton, Dickinson and Company were worth $9,194,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BDX. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company in the third quarter valued at about $25,000. Steph & Co. lifted its stake in shares of Becton, Dickinson and Company by 95.6% in the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 65 shares during the period. SHP Wealth Management acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter worth approximately $26,000. Prosperity Bancshares Inc bought a new stake in Becton, Dickinson and Company in the fourth quarter valued at approximately $29,000. Finally, WPG Advisers LLC increased its position in Becton, Dickinson and Company by 64.2% during the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 61 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BDX. Argus dropped their price target on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research report on Monday, March 23rd. Evercore lifted their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 in a research note on Thursday, May 7th. Bank of America dropped their target price on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Stifel Nicolaus cut their price target on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. Finally, Piper Sandler lowered their price objective on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $181.00.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 5,188 shares of company stock worth $765,120. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Stock Up 1.0%

Shares of NYSE BDX opened at $152.90 on Thursday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The firm has a market cap of $42.13 billion, a PE ratio of 38.71, a P/E/G ratio of 10.71 and a beta of 0.21. The company’s fifty day simple moving average is $147.91 and its 200 day simple moving average is $169.71.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 12.62 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th were given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.